Alto Neuroscience Stock Analysis

ANRO Stock   16.71  0.06  0.36%   
At this time, Alto Neuroscience's Short and Long Term Debt Total is very stable compared to the past year. As of the 12th of February 2026, Short Term Debt is likely to grow to about 1.1 M, though Net Debt is likely to grow to (129.3 M). With a high degree of financial leverage come high-interest payments, which usually reduce Alto Neuroscience's Earnings Per Share (EPS).
 
Debt Ratio  
First Reported
2010-12-31
Previous Quarter
0.11
Current Value
0.1
Quarterly Volatility
0.54767974
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
At this time, Alto Neuroscience's Total Stockholder Equity is very stable compared to the past year. As of the 12th of February 2026, Liabilities And Stockholders Equity is likely to grow to about 214.4 M, while Common Stock Shares Outstanding is likely to drop about 20.5 M. . At this time, Alto Neuroscience's Price Book Value Ratio is very stable compared to the past year. As of the 12th of February 2026, Price To Book Ratio is likely to grow to 0.65, while Price To Sales Ratio is likely to drop 2,017.
Alto Neuroscience is undervalued with Real Value of 19.34 and Target Price of 31.13. The main objective of Alto Neuroscience stock analysis is to determine its intrinsic value, which is an estimate of what Alto Neuroscience is worth, separate from its market price. There are two main types of Alto Neuroscience's stock analysis: fundamental analysis and technical analysis.
The Alto Neuroscience stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Alto Neuroscience is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Alto Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience guide.

Alto Stock Analysis Notes

About 67.0% of the company shares are held by institutions such as insurance companies. The book value of Alto Neuroscience was presently reported as 4.11. The company recorded a loss per share of 2.3. Alto Neuroscience had not issued any dividends in recent years. For more info on Alto Neuroscience please contact B BCom at 650 200 0412 or go to https://www.altoneuroscience.com.

Alto Neuroscience Investment Alerts

Alto Neuroscience appears to be risky and price may revert if volatility continues
Net Loss for the year was (61.43 M) with profit before overhead, payroll, taxes, and interest of 0.
Alto Neuroscience generates negative cash flow from operations
Alto Neuroscience has a frail financial position based on the latest SEC disclosures
About 67.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Alto Neuroscience, Inc. Given Average Recommendation of Moderate Buy by Analysts - MarketBeat

Alto Largest EPS Surprises

Earnings surprises can significantly impact Alto Neuroscience's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-13
2024-09-30-0.56-0.62-0.0610 
2024-08-13
2024-06-30-0.53-0.6-0.0713 
2025-11-12
2025-09-30-0.64-0.520.1218 
View All Earnings Estimates

Alto Neuroscience Environmental, Social, and Governance (ESG) Scores

Alto Neuroscience's ESG score is a quantitative measure that evaluates Alto Neuroscience's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Alto Neuroscience's operations that may have significant financial implications and affect Alto Neuroscience's stock price as well as guide investors towards more socially responsible investments.

Alto Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 517.25 M.

Alto Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.31)(0.33)
Return On Capital Employed(0.37)(0.39)
Return On Assets(0.31)(0.33)
Return On Equity(0.47)(0.44)

Management Efficiency

Alto Neuroscience has return on total asset (ROA) of (0.2448) % which means that it has lost $0.2448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4501) %, meaning that it created substantial loss on money invested by shareholders. Alto Neuroscience's management efficiency ratios could be used to measure how well Alto Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of February 2026, Return On Tangible Assets is likely to drop to -0.33. In addition to that, Return On Capital Employed is likely to drop to -0.39. At this time, Alto Neuroscience's Total Assets are very stable compared to the past year. As of the 12th of February 2026, Non Current Assets Total is likely to grow to about 9.9 M, while Non Currrent Assets Other are likely to drop 3,420.
Last ReportedProjected for Next Year
Book Value Per Share 5.54  5.82 
Tangible Book Value Per Share 5.54  5.82 
Enterprise Value Over EBITDA 0.62  0.65 
Price Book Value Ratio 0.62  0.65 
Enterprise Value Multiple 0.62  0.65 
Price Fair Value 0.62  0.65 
Enterprise Value-54.3 M-51.6 M
The strategic initiatives led by Alto Neuroscience's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta
2.851
Return On Assets
(0.24)
Return On Equity
(0.45)

Technical Drivers

As of the 12th of February 2026, Alto Neuroscience shows the Risk Adjusted Performance of 0.1179, mean deviation of 4.04, and Downside Deviation of 6.33. Alto Neuroscience technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Alto Neuroscience Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Alto Neuroscience price series with the more recent values given greater weights.

Alto Neuroscience Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alto Neuroscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alto Neuroscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alto Neuroscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Alto Neuroscience Outstanding Bonds

Alto Neuroscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alto Neuroscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alto bonds can be classified according to their maturity, which is the date when Alto Neuroscience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Alto Neuroscience Predictive Daily Indicators

Alto Neuroscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Alto Neuroscience stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Alto Neuroscience Corporate Filings

F4
6th of January 2026
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10th of December 2025
Other Reports
ViewVerify
28th of November 2025
Other Reports
ViewVerify
8K
12th of November 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
27th of October 2025
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
8K
20th of October 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
10th of October 2025
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
F3
14th of August 2025
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify

Alto Neuroscience Forecast Models

Alto Neuroscience's time-series forecasting models are one of many Alto Neuroscience's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alto Neuroscience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Alto Neuroscience Bond Ratings

Alto Neuroscience financial ratings play a critical role in determining how much Alto Neuroscience have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Alto Neuroscience's borrowing costs.
Piotroski F Score
3
FrailView
Beneish M Score
(4.98)
Unlikely ManipulatorView

Alto Neuroscience Total Assets Over Time

Alto Neuroscience Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Alto Neuroscience uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Alto Neuroscience Debt Ratio

    
  10.0   
It appears that most of the Alto Neuroscience's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Alto Neuroscience's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Alto Neuroscience, which in turn will lower the firm's financial flexibility.

Alto Neuroscience Corporate Bonds Issued

Alto Short Long Term Debt Total

Short Long Term Debt Total

29.44 Million

At this time, Alto Neuroscience's Short and Long Term Debt Total is very stable compared to the past year.

About Alto Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Alto Neuroscience prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Alto shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Alto Neuroscience. By using and applying Alto Stock analysis, traders can create a robust methodology for identifying Alto entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(39.37)(41.34)
Operating Profit Margin(51.67)(54.25)
Net Loss(39.37)(41.34)
Gross Profit Margin 0.28  0.25 

Current Alto Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Alto analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Alto analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceConsensus# of Analysts
31.13Strong Buy8Odds
Alto Neuroscience current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Alto analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Alto stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Alto Neuroscience, talking to its executives and customers, or listening to Alto conference calls.
Alto Analyst Advice Details

Alto Stock Analysis Indicators

Alto Neuroscience stock analysis indicators help investors evaluate how Alto Neuroscience stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Alto Neuroscience shares will generate the highest return on investment. By understating and applying Alto Neuroscience stock analysis, traders can identify Alto Neuroscience position entry and exit signals to maximize returns.
Begin Period Cash Flow82.5 M
Long Term Debt11.6 M
Common Stock Shares Outstanding24.6 M
Total Stockholder Equity151.5 M
Total Cashflows From Investing Activities-2.1 M
Property Plant And Equipment Net7.7 M
Cash And Short Term Investments168.2 M
Cash168.2 M
Accounts Payable1.6 M
Net Debt-151.3 M
50 Day M A16.2238
Total Current Liabilities10 M
Other Operating Expenses68.6 M
Non Current Assets Total8.2 M
Non Currrent Assets Other4000.00
Stock Based Compensation7.6 M
When determining whether Alto Neuroscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alto Neuroscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alto Neuroscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alto Neuroscience Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Will Pharmaceuticals sector continue expanding? Could Alto diversify its offerings? Factors like these will boost the valuation of Alto Neuroscience. If investors know Alto will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alto Neuroscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.30)
Return On Assets
(0.24)
Return On Equity
(0.45)
Understanding Alto Neuroscience requires distinguishing between market price and book value, where the latter reflects Alto's accounting equity. The concept of intrinsic value - what Alto Neuroscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Alto Neuroscience's price substantially above or below its fundamental value.
Understanding that Alto Neuroscience's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alto Neuroscience represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Alto Neuroscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.